New trial aims to stop stomach bleeding before it starts

NCT ID NCT07168395

Not yet recruiting Disease control Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether treating enlarged stomach veins (gastric varices) early with a procedure called retrograde transvenous obliteration (RTO) can prevent dangerous bleeding. 68 adults with cirrhosis and gastric varices will be randomly assigned to either RTO or standard care with beta-blocker medication. Researchers will track bleeding episodes, survival, and complications over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Retrograde transvenous obliteration (RTO) procedure
What this could lead to: If successful, this could offer a way to prevent dangerous stomach variceal bleeding before it starts, potentially reducing emergency treatments and improving survival.
What could go wrong: This is a small, early-phase trial with only 68 participants. The procedure carries risks like bleeding or liver complications, and it may not prove better than current medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMPENSATED CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices Hemorrhage hepatic encephalopathy varicose disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC VARICES

More trials for these conditions

Other studies related to the condition(s) this trial covers.